<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>concurrent &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/concurrent/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 18:41:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>concurrent &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Lymphopenia emerges as earliest and most frequent blood toxicity in cervical cancer chemoradiation study</title>
		<link>https://bioengineer.org/lymphopenia-emerges-as-earliest-and-most-frequent-blood-toxicity-in-cervical-cancer-chemoradiation-study/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 18:41:27 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Adjuvant]]></category>
		<category><![CDATA[adverse]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[chemoradiotherapy]]></category>
		<category><![CDATA[concurrent]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[hematological]]></category>
		<category><![CDATA[influencing]]></category>
		<category><![CDATA[postoperative]]></category>
		<category><![CDATA[spectrum]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=431897</guid>

					<description><![CDATA[When a patient with cervical cancer finishes radical surgery and then faces weeks of postoperative adjuvant concurrent chemoradiotherapy, the treatment that helps destroy residual cancer cells can also quietly undermine the blood system that keeps the body defended and oxygenated.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">431897</post-id>	</item>
	</channel>
</rss>
